Ocular TherapeutixTM Announces Exercise of Underwriters’ Option to Purchase Additional Shares
Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced that underwriters exercised their option to purchase an additional 558,750 shares at $21.50 per share, raising total shares sold to 4,283,750. This resulted in gross proceeds of approximately $92.1 million and net proceeds of around $86.1 million after expenses. The offering, managed by Jefferies LLC and Piper Sandler & Co., was executed under an effective shelf registration statement. Ocular Therapeutix specializes in innovative therapies for eye diseases, with its first product, DEXTENZA®, FDA-approved for treating post-surgery ocular inflammation.
- Total proceeds from the offering increased to approximately $92.1 million.
- Net proceeds after expenses amount to about $86.1 million, enhancing liquidity.
- Successful exercise of underwriters' option indicates strong demand.
- None.
Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the underwriters of its public offering that closed on December 18, 2020, have exercised in full their option to purchase an additional 558,750 shares of its common stock at the public offering price of
Jefferies LLC and Piper Sandler & Co. acted as joint book-running managers for the offering. Raymond James & Associates, Inc. and JMP Securities LLC acted as co-managers for the offering.
The offering was made pursuant to a shelf registration statement on Form S-3 that became effective upon filing with the Securities and Exchange Commission (SEC). The offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. Electronic copies of the final prospectus supplement and the accompanying prospectus for the offering are available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, NY 10022, by telephone: (877) 821-7388, or by email: Prospectus_Department@Jefferies.com or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or by email: prospectus@psc.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix is evaluating product candidates for the treatment of other ocular conditions including various retinal diseases, glaucoma, dry eye disease, and allergic conjunctivitis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005061/en/
FAQ
What was the total amount raised by Ocular Therapeutix in the recent offering?
How many shares did Ocular Therapeutix sell in total after the underwriters' option was exercised?
What price per share was set in the public offering of Ocular Therapeutix?
Who were the lead managers for Ocular Therapeutix's public offering?
What is the primary focus of Ocular Therapeutix, Inc.?
